Ampersand Biomedicines
Mengting Li is a knowledgeable researcher with a strong background in biotechnology and pharmacy. Currently serving as a Research Assistant at Ampersand Biomedicines since July 2023, Mengting Li focuses on developing antibody therapeutics to enhance target engagement and minimize off-tissue side effects. Previously, as a Graduate Researcher at Shandong University from September 2018 to June 2021, Mengting Li designed and implemented enzymatic synthesis systems, achieving substantial improvements in yield and cost-effectiveness. Additional experience includes an internship at Anhui HeGeng Biotech Engineering Co., Ltd., optimizing fermentation processes, and an undergraduate research role at Yichun University, where Mengting Li isolated and characterized halophilic microbes. Mengting Li holds a Master of Science in Biotechnology from Northeastern University and a Master of Pharmacy along with a Bachelor of Science in Pharmacy from Shandong University and Yichun University, respectively.
This person is not in any offices
Ampersand Biomedicines
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.